The big boom for German companies failed to materialize after the Covid reopening. Still, they want to continue to invest. They also hope their concerns will be addressed in the upcoming government consultations.
By Jörn Petring
The US pharmaceutical company Pfizer has renegotiated a contract from 2021 with the EU Commission. According to media reports, several hundred million euros in cancellation fees are at stake for Germany alone. The European Parliament wants to clarify the background. But instead of answers, Pfizer sends a catalog of questions.
By Eric Bonse
Beijing did not want to be dependent on foreign companies like BioNTech and therefore waited a long time before granting the first approval. The race has now been won by the domestic company CPSC.
By Redaktion Table
